Polθ-IN-10
Polθ-IN-10 is an orally active Polθ-pol inhibitor (with a human IC50 of 1.3 nM) that exhibits oral bioavailability in mice and rats. Polθ-IN-10 binds to the allosteric site of Polθ-pol, disrupts the microhomology-mediated end-joining DNA repair pathway, and inhibits CYP2C9 (IC50=1.63 μM). Polθ-IN-10 selectively inhibits the proliferation of HR-deficient cancer cells and induces apoptosis. Polθ-IN-10 is applicable to the research of HR-deficient cancers.
For research use only. We do not sell to patients.
- CAS No.: 3068829-46-6
- Formula: C27H24F4N6O3
- Molecular Weight:556.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
IC50 & Target
|
CYP2C9 1.63 μM (IC50) |
In Vitro
Polθ-IN-10 (Compound 20) (10-60 min) potently and selectively inhibits the polymerase activity of human Polθ, with an IC50 of 1.3 nM, and does not inhibit other human DNA polymerases at a concentration of 10 μM[1].
Polθ-IN-10 (3-10 d) selectively inhibits the proliferation of HR-deficient cancer cell lines with an IC50 value ranging from 2.49 to 5.60 μM, while exerting minimal effects on HR-proficient cancer cell lines and normal cell lines[1].
Polθ-IN-10 (0-50.0 μM) preferentially inhibits CYP2C9 with an IC50 of 1.63 μM; it shows weak inhibitory activity against other CYP subtypes and exhibits no inhibitory effect on CYP1A2 even at concentrations as high as 50 μM[1].
Polθ-IN-10 (1.25-20 μM; 3-14 d) selectively and dose-dependently inhibits colony formation in HR-deficient MDA-MB-436 cells, while exerting no significant effect on normal MCF10A cells[1].
Polθ-IN-10 (5-20 μM; 7 d) dose-dependently induces apoptosis in HR-deficient MDA-MB-436 cells[1].
Polθ-IN-10 (1.25-10 μM; 2-48 h) induces time- and dose-dependent DNA damage in homologous recombination-deficient MDA-MB-436 cells[1].
Polθ-IN-10 (100 μM; 30 min) directly binds to Polθ protein in MDA-MB-436 cells and enhances its thermal stability[1].
Polθ-IN-10 (1 μM; 60 min) exhibits excellent metabolic stability in human, mouse and rat liver microsomes, with a half-life ranging from 121.6 to 247.5 min[1].
Polθ-IN-10 (30 μM; acute exposure) exhibits weak inhibitory activity against hERG channels, inducing only 24.0% inhibition at the concentration of 30 μM, which suggests that it possesses favorable cardiac safety profiles[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HR-deficient cancer cell lines (MDA-MB-436, Capan-1, DLD-1 BRCA2-/-); HR-proficient/normal cell lines (DLD-1 BRCA2WT, MCF10A)
-
Concentration:Serial dilutions
-
Incubation Time:7 days (MDA-MB-436, Capan-1); 10 days (DLD-1 BRCA2-/-); 3 days (MCF10A)
-
Result:Exhibited antiproliferative activity with IC50 values of 2.49 μM in MDA-MB-436 cells, 5.60 μM in Capan-1 cells, and 4.63 μM in DLD-1 BRCA2-/- cells.
Showed minimal activity with an IC50 >20 μM in DLD-1 BRCA2WT and MCF10A cells.
-
Cell Line:HR-deficient breast cancer cell line MDA-MB-436
-
Concentration:5-20 μM
-
Incubation Time:7 days
-
Result:Induced apoptosis in 24.7%, 33.1%, and 57.8% of MDA-MB-436 cells at concentrations of 5, 10, and 20 μM respectively, compared to the control group.
-
Cell Line:HR-deficient breast cancer cell line MDA-MB-436
-
Concentration:5 μM (time-dependent assay); 1.25-10 μM (dose-dependent assay)
-
Incubation Time:2-12 h (time-dependent assay); 48 h (dose-dependent assay)
-
Result:Induced a time-dependent increase in γH2AX levels, with significant upregulation observed at 4 h and sustained through 12 h at 5 μM.
Also induced a dose-dependent increase in γH2AX levels, with significant upregulation at concentrations ≥2.5 μM after 48 h.
Parmacokinetics
| Species | Dose | Route | Cmax | Tmax | T1/2 | MRT0-t | MRT0-∞ | AUC0-t | AUC0-∞ | F | CL | Vd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 2 mg/kg | i.v. | 2580 ng/mL | / | 2.22 h | 2.03 h | 2.37 h | 4330 ng·h/mL | 4470 ng·h/mL | / | 0.45 L/h/kg | 1.06 L/kg |
| Mice[1] | 10 mg/kg | p.o. | 7560 ng/mL | 0.50 h | 1.65 h | 2.45 h | 2.59 h | 22800 ng·h/mL | 23100 ng·h/mL | 103.36 % | / | / |
| Rat[1] | 3 mg/kg | i.v. | 949 ng/mL | / | 1.48 h | 1.73 h | 1.73 h | 911 ng·h/mL | 911 ng·h/mL | / | 3.51 L/h/kg | 7.46 L/kg |
| Rat[1] | 30 mg/kg | p.o. | 1361 ng/mL | 1.00 h | 4.34 h | 4.02 h | 4.86 h | 5640 ng·h/mL | 5803 ng·h/mL | 63.71 % | / | / |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG mice (female, 18-20 g, subcutaneous xenograft of MDA-MB-436 BRCA1 mutant human breast cancer cells)[1]
-
Dosage:25 mg/kg; 50 mg/kg; 100 mg/kg
-
Administration:p.o.; once daily; 28 days
-
Result:Achieved tumor growth inhibition (TGI) rates of 45.49%, 51.99%, and 61.14% at doses of 25 mg/kg, 50 mg/kg, and 100 mg/kg, respectively.
Showed no significant mouse body weight loss across all treatment doses.
Detected a significant, dose-dependent increase in γH2AX (a DNA damage marker) expression in tumor tissue from treated mice.
Revealed no significant toxicity in histological analysis of heart, liver, spleen, lungs, and kidneys.
Chemical Information
-
CAS No. 3068829-46-6
-
Molecular Weight 556.51
-
Formula C27H24F4N6O3
-
SMILES
O=C(N(CC#CC1=NN=C(C=C1)C(O)(C)C)C2=CC=C(C=C2)F)[C@@H](N3C4=NC(C)=CC(C(F)(F)F)=C4)CNC3=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Polθ-IN-10
- 3068829-46-6
- DNA/RNA Synthesis
- Apoptosis
- Cytochrome P450
- HR-deficient cancer cells
- HR-deficient cancers
- Polθ-pol
- human Polθ
- HR-deficient cancer cell lines
- normal cell lines
- MCF10A cells
- MDA-MB-436 cells
- HR-proficient cell lines
- microhomology-mediated end joining DNA repair pathway
- Inhibitor
- inhibitor
- inhibit